Avalyn Pharma Inc. (AVLN) stock
AVLNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026
$27.92−1.84 (-6.18%)
Close on Nov 17, 2026Market cap $1.24BP/E –Yield –
Avalyn Pharma cash
Cash and short-term investments held at the end of each period.
Avalyn Pharma's cash was $352.43M at Jun 30, 2026. For fiscal 2025 it was $138.36M, up 477.6% from the year before.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $138.36M | +477.6% |
| FY2024 | Dec 31, 2024 | $23.96M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $352.43M | +1123.7% |
| Q1 FY2026 | Mar 31, 2026 | $123.13M | +414.0% |
| Q4 FY2025 | Dec 31, 2025 | $138.36M | – |
| Q2 FY2025 | Jun 30, 2025 | $61.30M | – |
| Q1 FY2025 | Mar 31, 2025 | $28.80M | – |
| Q4 FY2024 | Dec 31, 2024 | $23.96M | – |
See a number that looks wrong?